Investors are apparently expecting a hit to drug/biotech companies in the wake of the White House’s rescinding the proposal to ban drug rebates: https://www.wsj.com/articles/insurer-relief-could-come-at-pharmas-expense-11562857155 For instance, MRK ($78.82 as I’m typing) is down 8% on the week.